影片库

电影片库短剧片库动漫片库连续剧片库综艺片库
全部类型
国产剧港台剧日韩剧欧美剧香港剧台湾剧美国剧韩国剧日本剧海外剧Follow the official account反转爽剧
全部剧情
Sign inZip code: 100038青春偶像Follow the official accountObjective: To investigate the effect of intracoronary combined application of nitroprusside + recombinant human urokinase in patients with acute ST segment elevation myocardial infarction (STEMI) on the improvement of intracoronary artery reflow without reflow after emergency percutaneous coronary intervention (PCI) balloon dilation and opening. Methods: A total of 60 patients without reflow during STEMI emergency PCI admitted to the Department of Cardiology of Hebei Chest Hospital from March 2017 to March 2019 were selected as the research objects, and the patients were grouped by random number table method, with 30 cases in the observation group and 30 in the control group. The patients in the control group were treated with nitroprusside alone, and the patients in the observation group were treated with nitroprusside + recombinant human urokinase gen. The cardiac function parameters, blood flow classification of thrombolysis in myocardial infarction (TIMI), intraoperative and 24-hour postoperative bleeding, and the occurrence of major adverse cardiac events (MACE) within 1 month after surgery were analyzed and compared between the two groups. Results: After treatment, there were 28 (93.33%) and 20 (66.67%) patients in the observation group and the control group with TIMI blood flow grade 3, respectively, and the patients in the observation group were significantly better than the control group in terms of TIMI blood flow grading, and the difference was statistically significant (P<0.05). At 1 month after operation, the inner diameter of the left ventricular enddiastolic issue in the observation group was significantly lower than that in the control group 1 week after surgery, and was significantly lower than that of the control group. The left ventricular ejection fraction of the patients in the observation group was significantly higher than that in the control group at 1 week after operation, and the difference was statistically significant (P<0.05). The bleeding rates of the patients in the observation group and the control group were 16.67% (5/30) and 10.00% (3/30), respectively, and the incidence of MACE within 1 month after operation was 6.67% (2/30) and 20.00% (6/30), respectively, and there was no significant difference between the two groups (χ2= 0.144,P=0.704; χ2=2.401, P=0.254). Conclusion: The combined application of nitroprusside AND recombinant human urokinase gen in combination with intracoronary arterial therapy can effectively increase myocardial perfusion in patients without reflow during STEMI emergency PCI and improve cardiac function.Address：No. 15, Fuxing Road, Haidian District, Beijing, P.R. China, 100038Objective: To investigate the effect of intracoronary combined application of nitroprusside + recombinant human urokinase in patients with acute ST segment elevation myocardial infarction (STEMI) on the improvement of intracoronary artery reflow without reflow after emergency percutaneous coronary intervention (PCI) balloon dilation and opening. Methods: A total of 60 patients without reflow during STEMI emergency PCI admitted to the Department of Cardiology of Hebei Chest Hospital from March 2017 to March 2019 were selected as the research objects, and the patients were grouped by random number table method, with 30 cases in the observation group and 30 in the control group. The patients in the control group were treated with nitroprusside alone, and the patients in the observation group were treated with nitroprusside + recombinant human urokinase gen. The cardiac function parameters, blood flow classification of thrombolysis in myocardial infarction (TIMI), intraoperative and 24-hour postoperative bleeding, and the occurrence of major adverse cardiac events (MACE) within 1 month after surgery were analyzed and compared between the two groups. Results: After treatment, there were 28 (93.33%) and 20 (66.67%) patients in the observation group and the control group with TIMI blood flow grade 3, respectively, and the patients in the observation group were significantly better than the control group in terms of TIMI blood flow grading, and the difference was statistically significant (P<0.05). At 1 month after operation, the inner diameter of the left ventricular enddiastolic issue in the observation group was significantly lower than that in the control group 1 week after surgery, and was significantly lower than that of the control group. The left ventricular ejection fraction of the patients in the observation group was significantly higher than that in the control group at 1 week after operation, and the difference was statistically significant (P<0.05). The bleeding rates of the patients in the observation group and the control group were 16.67% (5/30) and 10.00% (3/30), respectively, and the incidence of MACE within 1 month after operation was 6.67% (2/30) and 20.00% (6/30), respectively, and there was no significant difference between the two groups (χ2= 0.144,P=0.704; χ2=2.401, P=0.254). Conclusion: The combined application of nitroprusside AND recombinant human urokinase gen in combination with intracoronary arterial therapy can effectively increase myocardial perfusion in patients without reflow during STEMI emergency PCI and improve cardiac function.NAPSTICAcute ST-segment elevation myocardial infarction, emergency percutaneous coronary intervention, nitroprusside, recombinant human urokinase, no refluxZip code: 100038Acute ST-segment elevation myocardial infarction, emergency percutaneous coronary intervention, nitroprusside, recombinant human urokinase, no refluxSign inAcute ST-segment elevation myocardial infarction, emergency percutaneous coronary intervention, nitroprusside, recombinant human urokinase, no refluxAddress：No. 15, Fuxing Road, Haidian District, Beijing, P.R. China, 100038Zip code: 100038Address：No. 15, Fuxing Road, Haidian District, Beijing, P.R. China, 100038
全部地区
Intracoronary Combined Application of Nitroprusside Sodium AND Recombinant Human Urokinase in Improving the Absence of Reflow in Emergency Percutaneous Coronary Intervention in Elderly Patients With Acute ST-Elevation Myocardial Infarction_China S&T Journals韩国香港Beijing ICP Preparation No. 10027328-24Institute of Scientific and Technical Information of China All rights reservedEmail: napstic@istic.ac.cnSign inBeijing ICP Preparation No. 10027328-24新加坡Address：No. 15, Fuxing Road, Haidian District, Beijing, P.R. China, 100038
全部语言
Intracoronary Combined Application of Nitroprusside Sodium AND Recombinant Human Urokinase in Improving the Absence of Reflow in Emergency Percutaneous Coronary Intervention in Elderly Patients With Acute ST-Elevation Myocardial Infarction_China S&T JournalsFollow the official accountObjective: To investigate the effect of intracoronary combined application of nitroprusside + recombinant human urokinase in patients with acute ST segment elevation myocardial infarction (STEMI) on the improvement of intracoronary artery reflow without reflow after emergency percutaneous coronary intervention (PCI) balloon dilation and opening. Methods: A total of 60 patients without reflow during STEMI emergency PCI admitted to the Department of Cardiology of Hebei Chest Hospital from March 2017 to March 2019 were selected as the research objects, and the patients were grouped by random number table method, with 30 cases in the observation group and 30 in the control group. The patients in the control group were treated with nitroprusside alone, and the patients in the observation group were treated with nitroprusside + recombinant human urokinase gen. The cardiac function parameters, blood flow classification of thrombolysis in myocardial infarction (TIMI), intraoperative and 24-hour postoperative bleeding, and the occurrence of major adverse cardiac events (MACE) within 1 month after surgery were analyzed and compared between the two groups. Results: After treatment, there were 28 (93.33%) and 20 (66.67%) patients in the observation group and the control group with TIMI blood flow grade 3, respectively, and the patients in the observation group were significantly better than the control group in terms of TIMI blood flow grading, and the difference was statistically significant (P<0.05). At 1 month after operation, the inner diameter of the left ventricular enddiastolic issue in the observation group was significantly lower than that in the control group 1 week after surgery, and was significantly lower than that of the control group. The left ventricular ejection fraction of the patients in the observation group was significantly higher than that in the control group at 1 week after operation, and the difference was statistically significant (P<0.05). The bleeding rates of the patients in the observation group and the control group were 16.67% (5/30) and 10.00% (3/30), respectively, and the incidence of MACE within 1 month after operation was 6.67% (2/30) and 20.00% (6/30), respectively, and there was no significant difference between the two groups (χ2= 0.144,P=0.704; χ2=2.401, P=0.254). Conclusion: The combined application of nitroprusside AND recombinant human urokinase gen in combination with intracoronary arterial therapy can effectively increase myocardial perfusion in patients without reflow during STEMI emergency PCI and improve cardiac function.闽南语韩语Beijing ICP Preparation No. 10027328-24NAPSTIC
全部时间
20242023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996199519941993199219911990
字母查找
ABCDEFGHIJKLMNOPQRSTUVWXYZ0-9
时间排序人气排序评分排序

影片库为你选出0部影片

繁
留言
首页
电影
短剧
动漫
连续剧
综艺